Kewalramani Takes Helm at Vertex

Restricted access

In the spring of 2020, nephrologist Reshma Kewalramani, MD, FASN, will assume the mantle of president and CEO of Vertex (Boston), a biotechnology company with revenues of $3.04 billion for fiscal year 2018. She will move up from her current position as executive vice president for global medicines development and medical affairs and chief medical officer at the company.

Kewalramani will follow Jeffrey Leiden, MD, PhD, who served in these roles for seven years and who oversaw hearty growth. According to Statnews.com, Vertex’s share price rose 360% and its sales doubled to just over $3 billion annually in

Save